Our previous studies demonstrated the predictive potential of pre-treatment plasma levels of homeobox protein SIX2 (SIX2) AAb (24) and lgG4 AAb targeting programmed cell death protein 1 (PDCD1) (25) for ICIs therapy efficacy in NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.